Disease · MONDO_0003799
conjunctivitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. conjunctivitis. Diseases, record MONDO_0003799. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003799
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- conjunctiva inflammation, conjunctivitis (disease), inflammation of conjunctiva, pink eye
- Open Targets
- Highest stage of its drugs
- Approval, for 12 of its 26 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZITHROMYCIN | CHEMBL529 | Small molecule | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Approval | EMA Human Drugs | 2 | 1 | 1 | Drugs and targets |
| GATIFLOXACIN | CHEMBL31 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| GENTAMICIN SULFATE | CHEMBL6067484 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| LEVOFLOXACIN | CHEMBL5315124 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| MINOCYCLINE HYDROCHLORIDE | CHEMBL1200881 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| MOXIFLOXACIN HYDROCHLORIDE | CHEMBL1200735 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| NATAMYCIN | CHEMBL1200656 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| SULFACETAMIDE | CHEMBL455 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TACROLIMUS | CHEMBL3989887 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Approval | https://conductscience.org/library/genes/2280 | Drugs and targets |
| ITGAL | Integrin alpha-L/beta-2 (LFA-1) | 1 | Integrin alpha-L/beta-2 (LFA-1) antagonist | Phase 1 | https://conductscience.org/library/genes/3683 | Drugs and targets |
| ITGB2 | Integrin alpha-L/beta-2 (LFA-1) | 1 | Integrin alpha-L/beta-2 (LFA-1) antagonist | Phase 1 | https://conductscience.org/library/genes/3689 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Approval | https://conductscience.org/library/genes/5478 | Drugs and targets |
| SIGLEC8 | Sialic acid-binding Ig-like lectin 8 | 1 | Sialic acid-binding Ig-like lectin 8 inhibitor | Unknown | https://conductscience.org/library/genes/27181 | Drugs and targets |
| TOP2A | DNA topoisomerase II | 1 | DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| TOP2B | DNA topoisomerase II | 1 | DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7155 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04981717 | A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat | Phase 3 | 446 | 2024-06-11 | Allergic Rhinitis Due to Cat Allergy | FRENESLERBART | Its record names the disease | ClinicalTrials.gov |
| NCT05430919 | Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants | Phase 2 | 217 | 2024-11-19 | Allergic Rhinitis, Conjunctivitis | UMESOLERBART | Its record names the disease | ClinicalTrials.gov |
| NCT02472223 | Reducing Adenoviral Patient Infected Days | Not applicable | 28 | 2021-01-06 | Conjunctivitis, Adenoviral Conjunctivitis | POVIDONE-IODINE | Its record names the disease | ClinicalTrials.gov |
| NCT00081835 | Evaluation and Treatment of Eye Complications of Vaccinia Vaccination | Phase 2 | 400 | Vaccinia | VACCINIA IMMUNE GLOBULIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06624384 | Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 | Phase 1 | 150 | Ocular Surface Symptom, Ocular Surface Disease, Eye Pain, Eye Inflammation | CYCLOSPORINE, LIFITEGRAST | Its record names the disease | ClinicalTrials.gov | |
| NCT00732446 | Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis | Phase 3 | 100 | Blepharitis, Conjunctivitis, Keratitis | DEXAMETHASONE, MOXIFLOXACIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01600365 | Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus | Phase 3 | 22 | Conjunctivitis, Adenovirus. | GANCICLOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT01721694 | Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection | Phase 3 | 0 | Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial | AZITHROMYCIN, LOTEPREDNOL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| REGN1908-1909 vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study | 2 of 224 | 2 of 222 | 446 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Number of Participants With Adverse Event of Special Interests (AESIs) Throughout the Study | 2 of 224 | 0 of 222 | 446 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs) Throughout the Study | 2 of 224 | 2 of 222 | 446 | NCT04981717 | Trial comparisons |
| R1908-1909 600 mg vs Placebo: deaths from any cause | 0 of 218 | 0 of 222 | 440 | NCT04981717 | Trial comparisons |
| R1908-1909 600 mg vs Placebo: serious adverse events | 2 of 218 | 2 of 222 | 440 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Incidence of Treatment-emergent ADAs to REGN1909 Throughout the Study | 5 of 210 | 5 of 213 | 423 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Incidence of Treatment-emergent Anti-drug Antibodies (ADAs) to REGN1908 Throughout the Study | 6 of 210 | 4 of 213 | 423 | NCT04981717 | Trial comparisons |
| Betadine 5% vs Artificial Tears: deaths from any cause | 1 of 16 | 0 of 12 | 28 | NCT02472223 | Trial comparisons |
| Betadine 5% vs Artificial Tears: serious adverse events | 0 of 16 | 0 of 12 | 28 | NCT02472223 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003799
GET https://conductscience.org/api/diseases/v1/MONDO_0003799/drugs?page=2